6,678 trials
Gastroesophageal Reflux Disease
Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms
Coronary Artery Disease · Angiotensin Converting Enzyme · Angiotensin Receptor Blockers
Primary: Tissue-type Plasminogen Activator (t-PA) Antigen Response — 14.36; 14.05; 11.97; 27.65 ng/mL — p=0.28
Type 2 Diabetes
Primary: Mean Change in Glycosylated Hemoglobin (A1C) — -0.71; -0.94 percentage of Hb — p=0.165
Healthy
Primary: Percent Mean Change From Baseline of International Normalized Ratio (INR) — 0.0452; 0.1605 percent change
COPD
Primary: Bronchodilator Response:Peak FEV1(L)(Forced Expiratory Volume in One Second)- — 1.74; 1.82 liters — p=0.027
Anxiety
Primary: Change in VAS Anxiety Score Relative to Baseline After Premedication — 0.35; 0.70; 0.65; 0.25 Centimeter
Hypertension
Primary: Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12 — 47.49; 45.93; -4.40; -3.69 Millimeter of mercury (mmHg) — p=0.5943
Healthy
Primary: % Platelet Inhibition — 23.4; 24.6; 41.2; 59 percentage of platelet inhibition
Non Small Cell Lung Carcinoma
Primary: Objective Response Rate(ORR) — 31.2 Percent of participants
Non Erosive Reflux Disease · Chronic Gastritis
Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
Urinary Incontinence
Primary: Objective Treatment Success at 12 Months — 80.8; 77.7 percentage of participants
Sepsis
Primary: Volume of Distribution (Vd) — 28.52 liters
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants